Education
About Us
Working with TipRanks
Follow Us
Lyell Immunopharma (LYEL)
NASDAQ:LYEL
Lyell Immunopharma (LYEL) Ownership Overview
17.85% Insiders
7.03% Mutual Funds
31.04% Other Institutional Investors
6.74% ETFs
37.33% Public Companies and
Individual Investors
The ownership structure of Lyell Immunopharma (LYEL) stock is a mix of institutional, retail, and individual investors. Approximately 44.82% of the company’s stock is owned by Institutional Investors, 17.85% is owned by Insiders, and 37.33% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
Date | Name | Activity | Value |
|---|---|---|---|
| Mar 25, 2025 | Sumant Ramachandra Director | xxxxxxxxxxxxx | $114000 |
| Mar 18, 2025 | xxxxxxxxxxxxx | $110000 | |
| Mar 18, 2025 | Lynn Seely President & Ceo,director | xxxxxxxxxxxxx | $105000 |
| Mar 18, 2025 | Richard Klausner Director | xxxxxxxxxxxxx | $94800 |
Recent Hedge Fund Trading Activity
Date | Firm | Activity | Value |
|---|---|---|---|
| Dec 31, 2024 | xxxxxxxxxxxxx | $33367 |
Top Shareholders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 36,477,716 | Insider | 14.50% | 21,339,464 | |
| 9,353,045 | Institution | 3.17% | 5,471,531 | |
| 8,163,116 | Institution | 2.77% | 4,775,423 | |
| 8,061,028 | Institution | 2.73% | 4,715,701 | |
| 4,942,827 | Institution | 1.67% | 2,891,554 | |
| 4,685,614 | Insider | 1.59% | 2,741,084 | |
| 3,653,199 | Insider | 1.24% | 2,137,121 | |
| 1,824,893 | Institution | 0.62% | 1,067,562 | |
| 1,673,698 | Institution | 0.57% | 979,113 | |
| 1,147,315 | Institution | 0.39% | 671,179 |
Top Mutual Fund Holders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 8,163,116 | Institution | 2.77% | 4,775,423 | |
| 4,942,827 | Institution | 1.67% | 2,891,554 | |
| 1,824,893 | Institution | 0.62% | 1,067,562 | |
| 1,673,698 | Institution | 0.57% | 979,113 | |
| 1,147,315 | Institution | 0.39% | 671,179 | |
| 873,516 | Institution | 0.30% | 511,007 | |
| 380,074 | Institution | 0.13% | 222,343 | |
| 361,243 | Institution | 0.12% | 211,327 | |
| 290,053 | Institution | 0.10% | 169,681 | |
| 187,126 | Institution | 0.06% | 109,469 |
Top ETF Holders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 5,640,251 | Institution | 1.91% | 3,329,440 | |
| 4,449,444 | Institution | 1.51% | 2,604,705 | |
| 2,522,865 | Institution | 0.85% | 1,489,247 | |
| 1,484,947 | Institution | 0.50% | 869,288 | |
| 879,635 | Institution | 0.30% | 533,323 | |
| 817,425 | Institution | 0.28% | 478,521 | |
| 717,695 | Institution | 0.24% | 423,655 | |
| 366,136 | Institution | 0.12% | 214,336 | |
| 350,118 | Institution | 0.12% | 206,675 | |
| 343,703 | Institution | 0.12% | 201,204 |
FAQ
Who Owns Lyell Immunopharma (LYEL)?
According to the latest TipRanks data, approximately 31.04% of the company's stock is held by institutional investors, 17.85% is held by insiders, and 37.33% is held by retail investors.
What percentage of Lyell Immunopharma (LYEL) stock is held by institutional investors?
According to the latest TipRanks data, approximately 31.04% of Lyell Immunopharma (LYEL) stock is held by institutional investors.
What percentage of Lyell Immunopharma (LYEL) stock is held by retail investors?
According to the latest TipRanks data, approximately 37.33% of Lyell Immunopharma (LYEL) stock is held by retail investors.
Who owns the most shares of Lyell Immunopharma (LYEL)?
Robert Nelsen owns the most shares of Lyell Immunopharma (LYEL).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.